152 related articles for article (PubMed ID: 30679780)
1. Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.
Evans TRJ; Dean E; Molife LR; Lopez J; Ranson M; El-Khouly F; Zubairi I; Savulsky C; Reyderman L; Jia Y; Sweeting L; Greystoke A; Barriuso J; Kristeleit R
Br J Cancer; 2019 Feb; 120(4):379-386. PubMed ID: 30679780
[TBL] [Abstract][Full Text] [Related]
2. A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine.
Twelves C; Anthoney A; Savulsky CI; Guo M; Reyderman L; Cresti N; Semiglazov V; Timcheva C; Zubairi I; Morrison R; Plummer R; Evans TRJ
Br J Cancer; 2019 Mar; 120(6):579-586. PubMed ID: 30783204
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).
Schafer ES; Rau RE; Berg S; Liu X; Minard CG; D'Adamo D; Scott R; Reyderman L; Martinez G; Devarajan S; Reid JM; Fox E; Weigel BJ; Blaney SM
Pediatr Blood Cancer; 2018 Aug; 65(8):e27066. PubMed ID: 29719113
[TBL] [Abstract][Full Text] [Related]
4. Eribulin mesylate in patients with refractory cancers: a Phase I study.
Mukohara T; Nagai S; Mukai H; Namiki M; Minami H
Invest New Drugs; 2012 Oct; 30(5):1926-33. PubMed ID: 21887501
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors.
Tan AR; Rubin EH; Walton DC; Shuster DE; Wong YN; Fang F; Ashworth S; Rosen LS
Clin Cancer Res; 2009 Jun; 15(12):4213-9. PubMed ID: 19509146
[TBL] [Abstract][Full Text] [Related]
6. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.
Pernas S; Martin M; Kaufman PA; Gil-Martin M; Gomez Pardo P; Lopez-Tarruella S; Manso L; Ciruelos E; Perez-Fidalgo JA; Hernando C; Ademuyiwa FO; Weilbaecher K; Mayer I; Pluard TJ; Martinez Garcia M; Vahdat L; Perez-Garcia J; Wach A; Barker D; Fung S; Romagnoli B; Cortes J
Lancet Oncol; 2018 Jun; 19(6):812-824. PubMed ID: 29706375
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.
Koczywas M; Frankel PH; Synold TW; Lenz HJ; Mortimer JE; El-Khoueiry AB; Gandara DR; Cristea MC; Chung VM; Lim D; Reckamp KL; Lau DH; Doyle LA; Ruel C; Carroll MI; Newman EM
Br J Cancer; 2014 Dec; 111(12):2268-74. PubMed ID: 25349975
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies.
Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH
Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177
[TBL] [Abstract][Full Text] [Related]
9. A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer.
Sakiyama T; Tsurutani J; Iwasa T; Kawakami H; Nonagase Y; Yoshida T; Tanaka K; Fujisaka Y; Kurata T; Komoike Y; Nishio K; Nakagawa K
Br J Cancer; 2015 Mar; 112(5):819-24. PubMed ID: 25654665
[TBL] [Abstract][Full Text] [Related]
10. Phase Ib/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib.
Ida H; Shimizu T; Nishino M; Nakamura Y; Yazaki S; Katsuya Y; Sato J; Koyama T; Iwasa S; Sudo K; Kondo S; Yonemori K; Shitara K; Shiono S; Matsuoka D; Yasuda K; Otake Y; Suzuki T; Takase T; Takashima S; Yamaguchi K; Semba T; Yamamoto N
Cancer Res Commun; 2023 Jul; 3(7):1189-1199. PubMed ID: 37435605
[TBL] [Abstract][Full Text] [Related]
11. A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer.
Goel S; Swami U; Kumar K; Dittrich C; Reyderman L; Jain M; Aisner J; Song J; Petrylak DP
Cancer Chemother Pharmacol; 2019 Sep; 84(3):567-578. PubMed ID: 31190276
[TBL] [Abstract][Full Text] [Related]
12. A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers.
Roviello G; Milani M; Gobbi A; Cappelletti MR; Zanotti L; Senti C; Bottini A; Strina C; Sigala S; Generali D
Clin Breast Cancer; 2016 Jun; 16(3):e57-9. PubMed ID: 26943987
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer.
Lee JS; Yost SE; Blanchard S; Schmolze D; Yin HH; Pillai R; Robinson K; Tang A; Martinez N; Portnow J; Wen W; Yim JH; Brauer HA; Ren Y; Luu T; Mortimer J; Yuan Y
Breast Cancer Res; 2019 Nov; 21(1):119. PubMed ID: 31703728
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort.
Masuda N; Ono M; Mukohara T; Yasojima H; Shimoi T; Kobayashi K; Harano K; Mizutani M; Tanioka M; Takahashi S; Kogawa T; Suzuki T; Okumura S; Takase T; Nagai R; Semba T; Zhao ZM; Ren M; Yonemori K
Eur J Cancer; 2022 Jun; 168():108-118. PubMed ID: 35500404
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.
Devriese LA; Witteveen PO; Marchetti S; Mergui-Roelvink M; Reyderman L; Wanders J; Jenner A; Edwards G; Beijnen JH; Voest EE; Schellens JH
Cancer Chemother Pharmacol; 2012 Dec; 70(6):823-32. PubMed ID: 23010853
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial.
Morgan RJ; Synold TW; Longmate JA; Quinn DI; Gandara D; Lenz HJ; Ruel C; Xi B; Lewis MD; Colevas AD; Doroshow J; Newman EM
Cancer Chemother Pharmacol; 2015 Nov; 76(5):897-907. PubMed ID: 26362045
[TBL] [Abstract][Full Text] [Related]
17. Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors.
Sato J; Shimizu T; Koyama T; Iwasa S; Shimomura A; Kondo S; Kitano S; Yonemori K; Fujiwara Y; Tamura K; Suzuki T; Takase T; Nagai R; Yamaguchi K; Semba T; Zhao ZM; Ren M; Yamamoto N
Clin Cancer Res; 2022 May; 28(9):1783-1791. PubMed ID: 35180771
[TBL] [Abstract][Full Text] [Related]
18. Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study.
Hattori M; Ishiguro H; Masuda N; Yoshimura A; Ohtani S; Yasojima H; Morita S; Ohno S; Iwata H
Breast Cancer; 2018 Jan; 25(1):108-117. PubMed ID: 28861862
[TBL] [Abstract][Full Text] [Related]
19. Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.
Reda M; Macaire P; Bellio H; Uwer L; Ilie S; Lorgis V; Hennequin A; Ladoire S; Rederstorff E; Fumoleau P; Isambert N; Bonnin N; You B; Freyer G; Desmoulins I; Schmitt A
Cancer Chemother Pharmacol; 2022 Feb; 89(2):197-208. PubMed ID: 34997290
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.
Devriese LA; Witteveen PE; Wanders J; Law K; Edwards G; Reyderman L; Copalu W; Peng F; Marchetti S; Beijnen JH; Huitema AD; Voest EE; Schellens JH
Br J Clin Pharmacol; 2013 Feb; 75(2):507-15. PubMed ID: 22803519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
